Puma Biotechnology Inc (PBYI) analyst actions
Rating and price-target actions on PBYI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PBYI overview →
3 measured PBYI analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer | Press release | -0.37% | +0.84% | |
| Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer | Press release | -2.56% | +3.65% | |
| Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer | Press release | -5.52% | -2.05% |
Keep exploring
More PBYI: earnings → · SEC filings → · PBYI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 275 | +0.08% | 51% |
| LivaNova PLC - Ordinary Shares (LIVN) | 275 | +0.04% | 51% |
| PRANA BIOTECH (PRAN) | 274 | 0.00% | 48% |
| Solana Company - Class A (HSDT) | 272 | -1.20% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.